EXPOSURE-RESPONSE RELATIONSHIPS FOR EFFICACY AND SAFETY OF FILGOTINIB AND ITS METABOLITE GS-829845 IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY

Amy Meng  ^1    
1 Gilead Sciences, Inc

Topic
Disease Mechanisms, IBD

Session
IBD: Clinical trials poster I

Conference
UEG Week Virtual 2021